Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Research
Cancer Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Computer Resources
      • Highly Cited Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Early Career Award
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citations
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Molecular and Cellular Biology

Abstract 4165: Differential pathway activation associated with domain-specific PIK3CA mutations

Christina Yau, Stephen Benz, Charles Vaske, Sam Ng, Josh Stuart and Christopher C. Benz
Christina Yau
1Buck Institute for Age Research, Novato, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stephen Benz
2Five3 Genomics, Santa Cruz, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Charles Vaske
2Five3 Genomics, Santa Cruz, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sam Ng
3University of California, Santa Cruz, Santa Cruz, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Josh Stuart
3University of California, Santa Cruz, Santa Cruz, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher C. Benz
1Buck Institute for Age Research, Novato, CA;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2014-4165 Published October 2014
  • Article
  • Info & Metrics
Loading
Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA

Abstract

A recent study of the mutation landscape of >3000 cancers across 12 major cancer types from the Cancer Genome Atlas (TCGA) program revealed PIK3CA as the second most commonly mutated gene, occurring at >10% frequency in 8 types of cancer. Limited preclinical evidence suggested that mutations affecting PIK3CA catalytic vs. non-catalytic domains can produce different phenotypic consequences; however, whether domain-specific PIK3CA mutations results in distinct pathway consequences across multiple cancer types remain unclear. Thus, we used the PARADIGM algorithm, which integrates gene expression and copy number data into a superimposed pathway structure, to infer the activities of ∼13K pathway features and compared the signaling consequences associated with different domain-specific PIK3CA mutations within the TCGA Pan-Cancer dataset. Restricting to tumors harboring missense mutations in the coding region of a single PIK3CA domain resulted in 447 unique cases. PIK3CA mutations are distributed across the domains as follows: adaptor binding domain (ABD) = 23, Ras-binding domain (RBD) = 1, C2 = 50, helical = 199, and kinase = 174. Interestingly, the distribution of PIK3CA mutations among the domains is significantly different across cancer types (chi-square test p < 0.0001); of note, kinase domain mutations account for >50% of breast cancer PIK3CA mutations, while mutations in the helical domain predominate in head-and-neck and lung squamous carcinomas. Employing logistic regression and adjusting for cancer type, we identified 711 pathway features associated with kinase domain mutations (p < 0.05). As expected for gain-of-function mutations, the inferred activity of the PI3K catalytic subunit appeared elevated among kinase domain mutations; and pathway enrichment analysis identified G-alpha (12/13) signaling events as the top enriched pathway among all interconnected pathway features (FDR-corrected EASE score = 0.0001). Interestingly, although the PI3K complexes appeared more activated in the kinase domain mutants, other constituents of the G-alpha (12/13) pathway, such as RHO GTPase complexes, showed lower activity. Similarly, 1115 pathway features were identified as associated with helical domain PIK3CA mutations. Pathway enrichment and sub-network analysis independently identified lower activation of proliferation-related (FOXM1, MYC and PLK1) pathways as a key characteristic of the helical domain relative to other PIK3CA mutants. Altogether, these findings demonstrate that somatic mutations in different PIK3CA domains across 12 different cancer types produce distinct patterns of pathway activation, suggesting that domain-specific mutants likely have different oncogenic consequences, perhaps even within the same tumor type, and that targeted PIK3CA inhibitors may show differential anticancer activity depending on the domain location of the PIK3CA mutation.

Citation Format: Christina Yau, Stephen Benz, Charles Vaske, Sam Ng, Josh Stuart, Christopher C. Benz. Differential pathway activation associated with domain-specific PIK3CA mutations. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4165. doi:10.1158/1538-7445.AM2014-4165

  • ©2014 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 74 (19 Supplement)
October 2014
Volume 74, Issue 19 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 4165: Differential pathway activation associated with domain-specific PIK3CA mutations
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract 4165: Differential pathway activation associated with domain-specific PIK3CA mutations
Christina Yau, Stephen Benz, Charles Vaske, Sam Ng, Josh Stuart and Christopher C. Benz
Cancer Res October 1 2014 (74) (19 Supplement) 4165; DOI: 10.1158/1538-7445.AM2014-4165

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 4165: Differential pathway activation associated with domain-specific PIK3CA mutations
Christina Yau, Stephen Benz, Charles Vaske, Sam Ng, Josh Stuart and Christopher C. Benz
Cancer Res October 1 2014 (74) (19 Supplement) 4165; DOI: 10.1158/1538-7445.AM2014-4165
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Molecular and Cellular Biology

  • Abstract DDT02-01: Inhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer
  • Abstract RAOS15-03: Pancreatic tumor stroma as a therapeutic target
  • Abstract LB-308: A novel data safe haven approach to bring analyses to the International Cancer Genome Consortium data
Show more Molecular and Cellular Biology

Poster Presentations - Proffered Abstracts

  • Abstract DDT02-01: Inhibition of the AAA-ATPase p97 with the first in class inhibitor CB-5083 as a novel approach to treat cancer
  • Abstract RAOS15-03: Pancreatic tumor stroma as a therapeutic target
  • Abstract LB-308: A novel data safe haven approach to bring analyses to the International Cancer Genome Consortium data
Show more Poster Presentations - Proffered Abstracts

Poster Presentations - Applications of Bioinformatics to Cancer Biology

  • Abstract 4167: Harvesting knowledge from unexploited genomic data: Estimating relative telomere length from targeted-resequencing
  • Abstract 4181: Accurate and fast detection and comparison of larger clinically relevant insertions and deletions
  • Abstract 4190: A survey of the most common methods of group randomization and distribution in preclinical in vivo studies
Show more Poster Presentations - Applications of Bioinformatics to Cancer Biology
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement